SCHEMBL5370673

SCHEMBL5370673

CCc1ccc(S(=O)(=O)Nc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)cc1C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.52
HDAC1 Q13547 4/20 0.52
HDAC8 Q9BY41 4/20 0.52
HDAC3 O15379 3/20 0.52
HDAC4 P56524 3/20 0.52
HDAC7 Q8WUI4 3/20 0.52
HDAC2 Q92769 3/20 0.52
HDAC10 Q969S8 3/20 0.52
HDAC11 Q96DB2 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
HDAC9 Q9UKV0 3/20 0.52
HDAC5 Q9UQL6 3/20 0.52
KIF11 P52732 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.49
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
PLAT P00750 1/20 0.48
UCHL1 P09936 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376936 0.92 POLB (0.52) PLAUHDAC1HDAC8HDAC3HDAC4
SCHEMBL5382304 0.88 MEN1 (0.55) PLAUHDAC1HDAC8HDAC3HDAC4
SCHEMBL5368389 0.87 POLB (0.60) PLAUHDAC1HDAC8HDAC3HDAC4
SCHEMBL5386619 0.86 HDAC1 (0.48) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL5371829 0.85 SMN1; SMN2 (0.52) PLAUHDAC1SMN1; SMN2LMNAPLAT
SCHEMBL5378681 0.85 MAPT (0.50) PLAUHDAC1HDAC8HDAC3HDAC11
SCHEMBL5376739 0.85 PTPN2 (0.62) MAPT
SCHEMBL5386444 0.84 PLAU (0.54) PLAUHDAC1HDAC8HDAC3HDAC4
SCHEMBL5378701 0.82 KIF11 (0.52) PLAUHDAC1HDAC8HDAC3HDAC4
SCHEMBL5378743 0.81 UCHL1 (0.53) PLAUUCHL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD PLAU 3190/4885HDAC1 416/4885HDAC8 882/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD PLAU 3215/4885HDAC1 396/4885HDAC8 924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.